Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
J Natl Cancer Inst
    June 2024
  1. TSAI YY, Nair KG, Barot SV, Xiang S, et al
    Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.
    J Natl Cancer Inst. 2024 Jun 20:djae143. doi: 10.1093.
    >> Share

  2. SONG Y, Loomans-Kropp H, Baugher RN, Somerville B, et al
    Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome.
    J Natl Cancer Inst. 2024;116:957-965.
    >> Share

  3. YATES J, Schaufelberger H, Steinacher R, Schar P, et al
    DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.
    J Natl Cancer Inst. 2024;116:974-982.
    >> Share

  4. RANSOHOFF DF
    Evaluating a blood test for Colon cancer screening: how simulation modeling can inform clinical policy making and research.
    J Natl Cancer Inst. 2024 Jun 6:djae125. doi: 10.1093.
    >> Share

  5. NASCIMENTO DE LIMA P, Van Den Puttelaar R, Knudsen AB, Hahn AI, et al
    Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Jun 6:djae124. doi: 10.1093.
    >> Share

    May 2024
  6. HOCHSTER HS, Catalano P, Weitz M, Mitchell EP, et al
    Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 May 22:djae114. doi: 10.1093.
    >> Share

  7. CORONADO GD, Bienen L, Burnett-Hartman A, Lee JK, et al
    Maximizing scarce colonoscopy resources: the crucial role of stool-based tests.
    J Natl Cancer Inst. 2024;116:647-652.
    >> Share

    April 2024
  8. SUN J, Zhao J, Zhou S, Li X, et al
    Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.
    J Natl Cancer Inst. 2024 Apr 22:djae089. doi: 10.1093.
    >> Share

  9. FANG A, Ugai T, Gurjao C, Zhong R, et al
    Alcohol and colorectal cancer risk subclassified by mutational signatures of DNA mismatch repair deficiency.
    J Natl Cancer Inst. 2024 Apr 4:djae078. doi: 10.1093.
    >> Share

    March 2024
  10. BEVER AM, Hang D, Lee DH, Tabung FK, et al
    Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.
    J Natl Cancer Inst. 2024 Mar 1:djae047. doi: 10.1093.
    >> Share

  11. GOPALANI SV, Saraiya M, Huang B, Tucker TC, et al
    Population-level incidence of HPV-positive oropharyngeal, cervical, and anal cancers by smoking status.
    J Natl Cancer Inst. 2024 Mar 1:djae054. doi: 10.1093.
    >> Share

    February 2024
  12. GOPALANI SV, Senkomago V, Rim SH, Saraiya M, et al
    Human papillomavirus-associated anal squamous cell carcinoma: sociodemographic, geographic, and county-level economic trends in incidence rates-United States, 2001-2019.
    J Natl Cancer Inst. 2024;116:275-282.
    >> Share

  13. MAHLA RS
    RE: Autoimmune disease and the risk of anal cancer in the US elderly population.
    J Natl Cancer Inst. 2024;116:338-339.
    >> Share

  14. HOWLADER N, Bhattacharya M, Scoppa S, Miller D, et al
    Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic.
    J Natl Cancer Inst. 2024;116:208-215.
    >> Share

  15. SONG M, Engels EA, Clarke MA, Kreimer AR, et al
    Autoimmune disease and the risk of anal cancer in the US population aged 66 years and over.
    J Natl Cancer Inst. 2024;116:309-315.
    >> Share

    January 2024
  16. HAAS CB, Engels EA, Palefsky JM, Clarke MA, et al
    Severe anal intraepithelial neoplasia trends and subsequent invasive anal cancer in the United States.
    J Natl Cancer Inst. 2024;116:97-104.
    >> Share

  17. STAR J, Siegel RL, Minihan AK, Smith RA, et al
    Colorectal cancer screening test exposure patterns in US adults ages 45-49 years, 2019-2021.
    J Natl Cancer Inst. 2024 Jan 4:djae003. doi: 10.1093.
    >> Share

    December 2023
  18. JABBOUR SK, Hochster HS
    Evolving paradigms in locally advanced rectal cancer: the means justify the ends.
    J Natl Cancer Inst. 2023;115:1439-1441.
    >> Share

  19. KENNECKE HF, Auer R, Cho M, Dasari NA, et al
    NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.
    J Natl Cancer Inst. 2023;115:1457-1464.
    >> Share

  20. PESANTEZ D, Ten Hoorn S, Machado I, Garcia-Albeniz X, et al
    Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
    J Natl Cancer Inst. 2023;115:1497-1505.
    >> Share

    August 2023
  21. CHEN Z, Song W, Shu XO, Wen W, et al
    Novel insights into genetic susceptibility for colorectal cancer from transcriptome-wide association and functional investigation.
    J Natl Cancer Inst. 2023 Aug 26:djad178. doi: 10.1093.
    >> Share

  22. REIF DE PAULA T, Keller DS
    A National Evaluation of Adjuvant Chemotherapy in pT4N0M0 Colon Cancer from the National Cancer Database.
    J Natl Cancer Inst. 2023 Aug 16:djad164. doi: 10.1093.
    >> Share

  23. DANIELS JP, Freedland SJ, Gresham G
    The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
    J Natl Cancer Inst. 2023 Aug 16:djad140. doi: 10.1093.
    >> Share

  24. HELTE E, Save-Soderbergh M, Larsson SC, Martling A, et al
    Disinfection by-products in drinking water and risk of colorectal cancer: a population-based cohort study.
    J Natl Cancer Inst. 2023 Aug 8:djad145. doi: 10.1093.
    >> Share

  25. BYRD DA, Fan W, Greathouse KL, Wu MC, et al
    The intratumor microbiome is associated with microsatellite instability.
    J Natl Cancer Inst. 2023;115:989-993.
    >> Share

    July 2023
  26. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome.
    J Natl Cancer Inst. 2023;115:853-860.
    >> Share

  27. ARONSON M, Gryfe R, Choi YH, Semotiuk K, et al
    Evaluating colonoscopy screening intervals in patients with Lynch syndrome from a large Canadian registry.
    J Natl Cancer Inst. 2023;115:778-787.
    >> Share

    June 2023
  28. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    >> Share

  29. YEN T, Patel SG
    Symptoms and early-onset colorectal cancer: red flags are common flags!
    J Natl Cancer Inst. 2023 Jun 24:djad093. doi: 10.1093.
    >> Share

    May 2023
  30. BREGNI G, Trevisi E, Saude Conde R, Vanhooren M, et al
    Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.
    J Natl Cancer Inst. 2023;115:505-513.
    >> Share

  31. BILLER LH, Ng K
    The "Scope" of Colorectal Cancer Screening in Lynch Syndrome: Is There an Optimal Interval?
    J Natl Cancer Inst. 2023 May 4:djad074. doi: 10.1093.
    >> Share

  32. FRITZ CDL, Otegbeye EE, Zong X, Demb J, et al
    Red-flag Signs and Symptoms for Earlier Diagnosis of Early-Onset Colorectal Cancer.
    J Natl Cancer Inst. 2023 May 4:djad068. doi: 10.1093.
    >> Share

    February 2023
  33. CORONADO GD, Ferrari RM, Barnes A, Castaneda SF, et al
    Characteristics of Patient Navigation Programs in the Cancer Moonshot ACCSIS Colorectal Cancer Screening Initiative.
    J Natl Cancer Inst. 2023 Feb 22:djad032. doi: 10.1093.
    >> Share

  34. CROSS AJ, Gunter MJ
    Ultra-processed foods and colorectal neoplasia: is there a link?
    J Natl Cancer Inst. 2023;115:117-119.
    >> Share

  35. SELBY K, Sedki M, Levine E, Kamineni A, et al
    Test performance metrics for breast, cervical, colon and lung cancer screening: a systematic review.
    J Natl Cancer Inst. 2023 Feb 8:djad028. doi: 10.1093.
    >> Share

    January 2023
  36. VOS JAM, Sert E, Busschers WB, Duineveld LAM, et al
    Detection of colon cancer recurrences during follow-up care by general practitioners versus surgeons.
    J Natl Cancer Inst. 2023 Jan 30:djad019. doi: 10.1093.
    >> Share

  37. DAVIS LE, Mahar AL, Strumpf EC
    Agreement between individual and neighbourhood income measures in patients with colorectal cancer in Canada.
    J Natl Cancer Inst. 2023 Jan 27:djad017. doi: 10.1093.
    >> Share

  38. MA W, Walker MM, Thuresson M, Roelstraete B, et al
    Cancer risk in patients with diverticular disease: A nationwide cohort study.
    J Natl Cancer Inst. 2023;115:62-70.
    >> Share

  39. ROMESSER PB, Sanchez-Vega F, Joshua Smith J
    A methylation-based prognostic signature in stage II colorectal patients: Considerations for clinical adoption.
    J Natl Cancer Inst. 2023;115:8-11.
    >> Share

    December 2022
  40. HANG D, Wang L, Fang Z, Du M, et al
    Ultra-processed food consumption and risk of colorectal cancer precursors: results from three prospective cohorts.
    J Natl Cancer Inst. 2022 Dec 7:djac221. doi: 10.1093.
    >> Share

    November 2022
  41. MURPHY N, Newton CC, Song M, Papadimitriou N, et al
    Body Mass Index and Molecular Subtypes of Colorectal Cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac215. doi: 10.1093.
    >> Share

  42. COLDITZ GA
    Combined individual participant data: highest level evidence on obesity and colorectal cancer molecular subtypes.
    J Natl Cancer Inst. 2022 Nov 29:djac216. doi: 10.1093.
    >> Share

  43. GALLICCHIO L, Devasia TP, Tonorezos E, Mollica MA, et al
    Estimation of the Number of Individuals Living With Metastatic Cancer in the United States.
    J Natl Cancer Inst. 2022;114:1476-1483.
    >> Share

    October 2022
  44. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
    Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
    J Natl Cancer Inst. 2022;114:1392-1399.
    >> Share

    September 2022
  45. YU H, Wang X, Bai L, Tang G, et al
    DNA Methylation Profile in CpG-depleted Regions Uncovers a High-Risk Subtype of Early-stage Colorectal Cancer.
    J Natl Cancer Inst. 2022 Sep 28. pii: 6726193. doi: 10.1093.
    >> Share

  46. ZHANG ER, Pfeiffer RM, Austin A, Clarke MA, et al
    Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015.
    J Natl Cancer Inst. 2022;114:1246-1252.
    >> Share

    June 2022
  47. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    >> Share

  48. MOSS JL, Pinto CN, Srinivasan S, Cronin KA, et al
    Enduring Cancer Disparities by Persistent Poverty, Rurality, and Race: 1990-1992 to 2014-2018.
    J Natl Cancer Inst. 2022;114:829-836.
    >> Share

  49. GOLDBERG RM, Adams R, Buyse M, Eng C, et al
    Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.
    J Natl Cancer Inst. 2022;114:819-828.
    >> Share

    May 2022

  50. Correction to: Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    J Natl Cancer Inst. 2022 May 20. pii: 6590000. doi: 10.1093.
    >> Share

  51. CASTANON A, Parmar D, Massat N, Sasieni P, et al
    Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study.
    J Natl Cancer Inst. 2022 May 16. pii: 6586300. doi: 10.1093.
    >> Share

  52. TIAN Y, Kim AE, Bien SA, Lin Y, et al
    Genome-Wide Interaction Analysis of Genetic Variants with Menopausal Hormone Therapy for Colorectal Cancer Risk.
    J Natl Cancer Inst. 2022 May 5. pii: 6581085. doi: 10.1093.
    >> Share

    February 2022
  53. LADABAUM U, Church TR, Feng Z, Ransohoff DF, et al
    Counting Advanced Pre-Cancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity.
    J Natl Cancer Inst. 2022 Feb 4. pii: 6522121. doi: 10.1093.
    >> Share

  54. HEIN DM, Deng W, Bleile M, Kazmi SA, et al
    Racial and Ethnic Differences in Genomic Profiling of Early-Onset Colorectal Cancer.
    J Natl Cancer Inst. 2022 Feb 2. pii: 6520467. doi: 10.1093.
    >> Share

    January 2022
  55. LEE LH, Davis L, Ylagan L, Omilian AR, et al
    Identification of a Subset of Stage I Colorectal Cancer Patients with High Recurrence Risk.
    J Natl Cancer Inst. 2022 Jan 30. pii: 6517508. doi: 10.1093.
    >> Share

  56. MURPHY N, Song M, Papadimitriou N, Carreras-Torres R, et al
    Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis.
    J Natl Cancer Inst. 2022 Jan 20. pii: 6512063. doi: 10.1093.
    >> Share

  57. ARCHAMBAULT AN, Jeon J, Lin Y, Thomas M, et al
    Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506525. doi: 10.1093.
    >> Share

  58. SHANKARAN V, Unger JM, Darke AK, Suga JM, et al
    S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients.
    J Natl Cancer Inst. 2022 Jan 4. pii: 6492636. doi: 10.1093.
    >> Share

  59. GIOVANNUCCI E
    Molecular Biologic and Epidemiologic Insights for Preventability of Colorectal Cancer.
    J Natl Cancer Inst. 2022 Jan 3. pii: 6493343. doi: 10.1093.
    >> Share

    December 2021
  60. WERNLY S, Datz C, Wernly B
    RE: Long-Term Colorectal Cancer Incidence and Mortality After Colonoscopy Screening According to Individuals' Risk Profiles.
    J Natl Cancer Inst. 2021 Dec 25. pii: 6483088. doi: 10.1093.
    >> Share

    November 2021
  61. JIN Z, Dixon JG, Fiskum JM, Parekh HD, et al
    Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
    J Natl Cancer Inst. 2021;113:1693-1704.
    >> Share

  62. CERCEK A, Chatila WK, Yaeger R, Walch H, et al
    A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.
    J Natl Cancer Inst. 2021;113:1683-1692.
    >> Share

  63. ENG C, Hochster H
    Early-Onset Colorectal Cancer: The Mystery Remains.
    J Natl Cancer Inst. 2021;113:1608-1610.
    >> Share

  64. YIN J, Cohen R, Jin Z, Liu H, et al
    Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
    J Natl Cancer Inst. 2021;113:1705-1713.
    >> Share

  65. JOSHI AD, Chan AT
    Racial Differences in Epigenetic Aging of the Colon: Implications for Colorectal Cancer.
    J Natl Cancer Inst. 2021;113:1618-1619.
    >> Share

  66. DEVALL M, Sun X, Yuan F, Cooper GS, et al
    Racial Disparities in Epigenetic Aging of the Right vs Left Colon.
    J Natl Cancer Inst. 2021;113:1779-1782.
    >> Share

    October 2021
  67. LIPSYC-SHARF M, Zhang S, Ou FS, Ma C, et al
    Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2021 Oct 12. pii: 6390822. doi: 10.1093.
    >> Share

    September 2021
  68. POST CCB, Stelloo E, Smit VTHBM, Ruano D, et al
    Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
    J Natl Cancer Inst. 2021;113:1212-1220.
    >> Share

    August 2021
  69. BREUER E, Hebeisen M, Schneider MA, Roth L, et al
    Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis.
    J Natl Cancer Inst. 2021;113:1027-1035.
    >> Share

    April 2021
  70. WAGNER AD, Grothey A, Andre T, Dixon JG, et al
    Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    J Natl Cancer Inst. 2021;113:400-407.
    >> Share

  71. ZAANAN A, Henriques J, Cohen R, Sefrioui D, et al
    Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin.
    J Natl Cancer Inst. 2021;113:496-500.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016